<DOC>
	<DOCNO>NCT02608242</DOCNO>
	<brief_summary>This Randomized , open-label , single-dose , 3-treatment , 3-period , 3-sequence crossover design .</brief_summary>
	<brief_title>PK Study YH22189 FDC Compared Combination Telmisartan/Amlodipine Rosuvastatin</brief_title>
	<detailed_description>This 6 3 cross-over study evaluate pharmacokinetics YH22189 FDC compare reference telmisartan/amlodipine rosuvastatin co-administered three group enrol healthy adult male subject fast condition . Subjects admit clinic evening Day 1 . All subject receive single oral dose YH22189 FDC telmisartan/amlodipine rosuvastatin administer morning Day 1 . All subject remain clinical unit completion assessment Day 2 include collection post-dose PK sample . Subjects return clinic pharmacokinetic sample schedule time . The three treatment period separate washout period .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Healthy male female body mass index ( BMI ) 18.5 25 kg/m2 Who suffer clinically significant disease Provision sign write informed consent History clinically significant disease A history drug abuse presence positive reaction drug abuse potential urine screening drug Administration investigational product within 3 month prior first dose Volunteers consider eligible clinical trial investigator ( study doctor ) due reason include laboratory test result , ECGs , vital sign Sitting blood pressure meeting follow criterion screen : 150 ≥ systolic blood pressure ≤100 ( mmHg ) 100 ≥ diastolic blood pressure ≤ 60 ( mmHg )</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>